Stockreport

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates 

Climb Bio, Inc.  (CLYM) 
PDF Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with in [Read more]